Navigation Links
Tianyin Pharmaceutical Co., Inc. Expects to Benefit from the Recently Published Guide to Pricing Reform for Medicine and Medical Services
Date:2/9/2010

CHENGDU, China, Feb. 9 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc., (NYSE Amex: TPI), a manufacturer and supplier of modernized traditional Chinese medicine ("TCM") and Western Pharmaceuticals based in Chengdu, China, today announced that it expects operational benefits from the recently published Guide to Reform of Pricing Mechanism of Medicine and Medical Services by the Chinese government.

On November 9, 2009, the Chinese National Development and Reform Commission, the Ministry of Health, and the Ministry of Human Resource and Social Security released a comprehensive Guide proposed to protect and foster the development of Chinese Medicine, which is aimed at benefiting the pharmaceutical companies focusing on specialized Chinese medicines like Tianyin Pharmaceuticals. The Guide requires that the pricing of medicine and medical services should reflect the quality differential. As such, the government will support higher sales prices set by the overall market for pharmaceutical companies which develop specialized products with strong efficacy for specific indications. The Guide also defined maximum profit margins for national and local distributors, which will further reduce the overall distribution costs of medicine and improve margins for the producers.

"We have spent considerable resources analyzing all aspects and implications of the new pricing mechanism Guide and are confident that Tianyin's portfolio will enjoy enhanced pricing as the benefits of several of our leading proprietary TCM products are well recognized by the marketplace," Dr. Jiang, Chairman and CEO of Tianyin Pharmaceutical Co., Inc., commented. "In addition, the Guide requires uniform pricing for all generic medicine which we believe will help us improve our gross margins through effective cost management and production efficiencies as overall production volumes increase. In addition, the Guide encourages new product innovation by allowing higher profit margins for companies like Tianyin who are focused on developing and commercializing differentiated drugs that meet consumer needs."

The Company has 23 drugs which are currently reimbursed by government medical insurance.

About Tianyin Pharmaceuticals

Tianyin is a manufacturer and supplier of modernized Traditional Chinese Medicine ("TCM") in China. It was established in 1994 and acquired by the current management team in August 2003. Tianyin currently has 48 SFDA approved products, 41 which are manufactured and marketed. 22 of these products are listed in the highly selective National Medicine Catalog of the National Medical Insurance program. Tianyin owns and operates two GMP manufacturing facilities and an R&D platform supported by leading Chinese academic institutions. The Company has also maintains a pipeline of 17 pharmaceutical products pending approval. Tianyin has an extensive nationwide distribution network throughout China with a sales force of 730 salespeople. The Company is headquartered in Chengdu, Sichuan Province with two manufacturing facilities and a total of 1,365 employees. For more information about Tianyin, please visit http://www.tianyinpharma.com .

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

    For more information, please contact:

    For the Company:
     Allen Tang, Ph.D., MBA, Assistant to the CEO China
     Tel:   +86-158-2122-5642
     Email: Allen.y.tang@gmail.com

    Investors:
     Mr. Matthew Hayden, HC International
     Tel:   +1-561-245-5155
     Email: matt.hayden@hcinternational.net

SOURCE Tianyin Pharmaceutical Co., Inc.

RELATED LINKS
http://www.tianyinpharma.com

'/>"/>

SOURCE Tianyin Pharmaceutical Co., Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2010 Financial Results
2. Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income
3. Tianyin Pharmaceutical Co., Inc. to Host Fiscal 2009 Earnings Conference Call on Thursday, September 24, 2009 at 10:30 a.m. ET
4. Tianyin Pharmaceutical Co., Inc. Obtains GMP Certification for Its New Production Facility
5. Tianyin Pharmaceutical, Co. to Present at the Rodman & Renshaw Annual Global Investment Conference on September 11 at 10:50 am ET
6. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Sanqi Tablets and Yinqiao Jiedu Tablets
7. Tianyin Pharmaceutical Co., Inc. Announces Cash Dividend to Common Stockholders
8. Tianyin Pharmaceutical Co., Inc. Adopts New Sales Strategy for Azithromycin Dispersible Tablets
9. Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2009 Second Quarter Earnings Conference Call on Wednesday, February 18, 2009 at 8:45 a.m. EST
10. Tianyin Pharmaceutical Co., Inc. Implements New Sales and Marketing Strategy to Drive Revenue Growth
11. Tianyin Pharmaceutical Co., Inc. Announces First Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... ... is proud to announce it has become the premiere team-building cooking event company in San ... world, such as Illumina, HP and Qualcomm, and is ranked #1 in its category on ... to its new team building format, a way for teams to not only interact with ...
(Date:3/23/2017)... , March 23, 2017  Northwest Biotherapeutics (OTCQB: ... personalized immune therapies for solid tumor cancers, today ... million financing it announced last Friday, March 17, ... several institutional investors securities totaling 28,843,692 shares, comprised ... and 10,000,000 shares of Class C Warrants pre-funded ...
(Date:3/23/2017)... LOUISVILLE, Colo. , March 23, 2017  GlobeImmune, ... purchase agreement for the sale of 12,835,490 shares of ... the  NantWorks  ecosystem of companies. In connection with the sale ... GlobeImmune $100,000 in cash and issue to GlobeImmune 200,000 ... common stock. "We are pleased to ...
(Date:3/23/2017)... ... March 23, 2017 , ... Ellen Matloff, president ... Technology Council (CTC) as a 2017 Women of Innovation® finalist. Matloff will be ... Awards Dinner. , The dinner recognizes women accomplished in science, technology, engineering and ...
Breaking Biology Technology:
(Date:2/24/2017)... , Feb. 24, 2017  EyeLock LLC, a leader of ... elite iris biometric solution on the latest Qualcomm® ... at Mobile World Congress 2017 (February 27 ... in Hall 3, Stand 3E10. ... Haven™ security platform—a combination of hardware, software ...
(Date:2/16/2017)... 2017  Genos, a community for personal genetic ... received Laboratory Accreditation from the College of American ... laboratories that meet stringent requirements around quality, accuracy ... "Genos is committed to maintaining the ... honored to be receiving CAP accreditation," said ...
(Date:2/10/2017)... Research and Markets has announced the addition ... and Commercial Aspects" to their offering. ... Biomarkers play an ... for selection of treatment as well for monitoring the results. ... in modern medicine. Biochip/microarray technologies and next generation sequencing are ...
Breaking Biology News(10 mins):